
Laboratoires Delbert
Pharmaceutical company specializing in regulatory affairs and sustainable medicine management, ensuring optimal patient care.
EUR | 2018 | 2019 | 2020 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
% growth | - | 87 % | 75 % |
EBITDA | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 |
% profit margin | 19 % | 8 % | 4 % |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Delbert Pharma is a pharmaceutical company focused on the acquisition, development, and commercialization of specialty medicines. Founded by experts in regulatory affairs, the company operates primarily in the European market, serving both healthcare providers and patients. Delbert Pharma's business model revolves around acquiring essential but often discontinued or hard-to-find medications, ensuring their continued availability in the market. This approach not only fills critical gaps in the healthcare system but also provides a steady revenue stream through the sale of these specialized drugs. The company is committed to social and environmental responsibility, partnering with organizations like Cyclamed to recycle unused and expired medicines, thereby protecting public health and the environment. Delbert Pharma collaborates with high-quality production and logistics partners across the European Union to maintain compliance with industry best practices and ensure the availability of their products. Recent expansions include the commercialization of amoxicillin in Ireland, further broadening their market reach.
Keywords: regulatory affairs, specialty medicines, healthcare, sustainability, European market, patient care, drug acquisition, environmental responsibility, Cyclamed, amoxicillin.